Form 4: Revolution Medicines Executive Sells Shares

Anthony Mancini, Chief Global Commercialization Officer at Revolution Medicines, Inc., reported a transaction involving the sale of common stock to cover tax obligations.

Summary

• Anthony Mancini, Chief Global Commercialization Officer of Revolution Medicines, Inc., engaged in a transaction on June 16, 2026.
• This transaction involved the sale of 4,615 shares of common stock.
• The sale was an automatic sell-to-cover to satisfy applicable withholding taxes upon the vesting of restricted stock units.
• The weighted average sale price was $156.1192, with individual trades ranging from $156.1105 to $156.8250.
• Following this transaction, Mancini beneficially owns 49,975 shares of common stock.
• This ownership includes 43,700 Restricted Stock Units and 190 shares acquired through the Employee Stock Purchase Plan on May 31, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sale was an automatic, tax-motivated transaction, not indicative of a lack of confidence in the company's future prospects.

Positives

• The sale was an automatic sell-to-cover, indicating a pre-planned mechanism to manage tax liabilities associated with equity compensation.
• The transaction was executed at a weighted average price of $156.1192, reflecting market value at the time of sale.
• Mancini retains a significant beneficial ownership of 49,975 shares, suggesting continued commitment to the company.

Negatives

• A portion of the executive's equity compensation was sold, which could be perceived negatively by some investors if not for the tax cover nature of the sale.
• The sale price, while reflecting market value, represents a disposition of company stock.

Risks

• The filing does not explicitly mention any new or emerging risks.
• Potential future tax liabilities related to equity compensation could necessitate further sell-to-cover transactions.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports a past transaction.

Management Comments

• "Pursuant to an automatic sell-to-cover, the shares were sold following the vesting of the restricted stock units solely to cover applicable withholding taxes."
• "This transaction was executed in multiple trades at prices ranging from $156.1105 to $156.8250. The price reported above reflects the weighted average price."
• "The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."

Industry Context

StockSavvy.ai notes that insider transactions, particularly sell-to-cover events for tax purposes, are common in the biotechnology and pharmaceutical sectors as executives receive equity compensation. The price range indicates active trading around the reported weighted average.

Stakeholder Impact

• Shareholders: The sale is a routine tax-related event and is not expected to significantly impact share price or investor sentiment, as it was an automatic sell-to-cover.
• Employees: This filing pertains to executive compensation and does not directly impact other employees.
• Management: The transaction reflects the standard management of equity compensation and associated tax liabilities.

Next Steps

• No specific next steps are outlined in this filing.

Key Dates

Keywords

Revolution Medicines, RVMD, Form 4, Insider Transaction, Stock Sale, Withholding Taxes, Restricted Stock Units, Employee Stock Purchase Plan, Anthony Mancini, Executive Compensation